Profile Details

Contact

★★★★★

☆☆☆☆☆

USD 80 /hr

★★★★★

☆☆☆☆☆

Hire Dr. Reham M.

United Arab Emirates

USD 80 /hr

Medical Communications Consultant & Writer

Profile Summary

A biomedical scientist with experience as an academic, scientific-medical communications (MedComms) consultant and writer, and an advocate of delivering value with real-world data and real-world evidence. I hold seven peer-reviewed publications in the molecular and cellular pathology field. My MedComms work includes liaising with Big Pharma, medical writing agencies, healthcare professionals, key opinion leaders, and academics; within the scope of publication planning, advisory board meetings, slide decks, tailored medical/clinical healthcare content, patient advocacy programs, and CME.

Subject Matter Expertise

• ★ Medical Writing
• ★ Healthcare Communications
• ☆ STEM
• ☆ Experiential Education
• ☆ Pharmaceutical Sciences
• ☆ Biologic & Biosimilar Development
• ☆ Pharmacogenomics
• ☆ Medicine
• ☆ Clinical Trials
• ☆ Neurology
• ☆ Pediatric Neurology
• ☆ Ophthalmology
• ☆ Women's Health
• ☆ Men's Health
• ☆ Oncology
• ☆ Precision Medicine
• ☆ Gastroenterology & Hepatology
• ☆ Cardiovascular Disease
• ☆ Clinical Laboratory Science
• ☆ Molecular Pathology
• ☆ Neuropathology
• ☆ Rare Diseases
• ☆ Rheumatology
• ☆ Medical Content Writing
• ☆ Continuing Medical Education (CME) Materials
• ☆ Patient Education Materials
• ☆ Research Summaries & Abstracts

Services

• Writing
• Research
• Consulting

Writing Clinical Trial Documentation, Medical Writing, General Proofreading & Editing

Research Fact Checking, Gray Literature Search, Systematic Literature Review, Secondary Data Collection

Consulting Healthcare Consulting

Work Experience

Medical Communications Consultant & Writer

Freelance

April 2016 - Present

Assistant Professor of Natural and Applied Sciences

University of Dubai

August 2017 - January 2020

Postdoctoral Fellow | Postgraduate researcher

United Arab Emirates University

March 2011 - April 2016

Science Advisor | Curriculum Support Specialist

Nord Anglia Education

August 2007 - March 2011

Research and Teaching Assistant

Jordan University of Science and Technology

August 2000 - August 2002

Education

PhD in Molecular Cellular Pathology

United Arab Emirates University

March 2011 - February 2015

MSc Clinical Biochemistry

University of Newcastle-upon-Tyne, UK

September 1996 - September 1997

Certifications

• Certification details not provided.

Publications

JOURNAL ARTICLE

Milhem, R.M., Ali, B.R.(2019). Disorders of FZ-CRD; Insights towards FZ-CRD folding and therapeutic landscape . Molecular Medicine. 26. (1).

Ahmad, M.A., Milhem, R.M., Panicker, N.G., Rizvi, T.A., Mustafa, F.(2016). Electrical characterization of DNA supported on nitrocellulose membranes . Scientific Reports. 6.

Milhem, R.M., Al-Gazali, L., Ali, B.R.(2015). Improved plasma membrane expression of the trafficking defective P344R mutant of muscle, skeletal, receptor tyrosine kinase (MuSK) causing congenital myasthenic syndrome . International Journal of Biochemistry and Cell Biology. 60. p. 119-129.

Matlik, H.N., Milhem, R.M., Saadeldin, I.Y., Al-Jaibeji, H.S., Al-Gazali, L., Ali, B.R.(2014). Clinical and molecular analysis of a novel COLQ missense mutation causing congenital myasthenic syndrome in a Syrian family . Pediatric Neurology. 51. (1). p. 165-169.

Milhem, R.M., Ben-Salem, S., Al-Gazali, L., Ali, B.R.(2014). Identification of the cellular mechanisms that modulate trafficking of frizzled family receptor 4 (FZD4) missense mutants associated with familial exudative vitreoretinopathy . Investigative Ophthalmology and Visual Science. 55. (6). p. 3423-3431.

Saadeldin, I.Y., Milhem, R.M., Al-Gazali, L., Ali, B.R.(2013). Novel KCNQ2 mutation in a large emirati family with benign familial neonatal seizures . Pediatric Neurology. 48. (1). p. 63-66.

Ali, B.R., Ben-Rebeh, I., John, A., Akawi, N.A., Milhem, R.M., Al-Shehhi, N.A., Al-Ameri, M.M., Al-Shamisi, S.A., Al-Gazali, L.(2011). Endoplasmic reticulum quality control is involved in the mechanism of endoglin-mediated hereditary haemorrhagic telangiectasia . PLoS ONE. 6. (10).